A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
Trial details
- Registry ID
- NCT07007637
- Drugs studied
- Sonelokimab
TrialRedline tracks 9 clinical trials sponsored by MoonLake Immunotherapeutics AG: 7 Phase 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisNCT05640245 | Adalimumab, Sonelokimab | Completed | 2023-09-05Actual |
| Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaNCT05322473 | Adalimumab, Sonelokimab (M1095) | Completed | 2023-05-09Actual |
Names as written in the registry records.
NCT06768671 · MoonLake Immunotherapeutics AG
Before: Estimated. After: Actual.
Before: Estimated. After: Actual.
Before: Active not recruiting. After: Completed.
NCT06641076 · MoonLake Immunotherapeutics AG
Before: Estimated. After: Actual.
Before: 4 Feb 2027. After: 28 May 2026.
NCT06641089 · MoonLake Immunotherapeutics AG
Before: 15 Jan 2027. After: 4 Jan 2027.
Before: Recruiting. After: Active not recruiting.
NCT05640245 · MoonLake Immunotherapeutics AG
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Response Rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50). After: Measure: Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12.
NCT05322473 · MoonLake Immunotherapeutics AG
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Hidradenitis Suppurativa Clinical Response 75. After: Measure: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 12.
NCT06411899 · MoonLake Immunotherapeutics AG
Before: Estimated. After: Actual.
Before: 17 Jun 2025. After: 2 Sep 2025.
Before: Active not recruiting. After: Completed.
NCT06411379 · MoonLake Immunotherapeutics AG
Before: Estimated. After: Actual.
Before: 17 Jun 2025. After: 14 Aug 2025.
Before: Active not recruiting. After: Completed.
NCT06768671 · MoonLake Immunotherapeutics AG
Before: 27 Mar 2026. After: 28 Sep 2026.
Before: Recruiting. After: Active not recruiting.
NCT06641076 · MoonLake Immunotherapeutics AG
Before: 15 Jan 2027. After: 4 Feb 2027.
Before: Recruiting. After: Active not recruiting.
NCT07223138 · MoonLake Immunotherapeutics AG
Before: Not yet recruiting. After: Enrolling by invitation.